Non-amine-based dopamine transporter (reuptake) inhibitors retain properties of amine-based progenitors

European Journal of Pharmacology

Volumn 479, Issue 1-3, 2003, Pages 41-51

  Madras, Bertha K ^a   Fahey, Michele A ^a   Miller, Gregory M ^a   De La Garza, Richard ^a   Goulet, Martin ^a   Spealman, Roger D ^a   Meltzer, Peter C ^b   George, Susan R ^c   O'Dowd, Brian F ^c   Bonab, Ali A ^d   Livni, Eli ^d   Fischman, Alan J ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ORGANIX INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Addiction; Anti depressant; Attention deficit hyperactivity disorder (ADHD); Cocaine; Dopamine transporter (DAT); Serotonin transporter (SERT)

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMFEBUTAMONE; AMINE; ANTIDEPRESSANT AGENT; BENZATROPINE; CITALOPRAM; COCAINE; DICHLOROPANE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; INDATRALINE; METHYLPHENIDATE; MONOAMINE; NEUROTRANSMITTER; NORADRENALIN TRANSPORTER; O 1059; O 1072; O 1109; O 1391; O 1783; O 1809; O 2098; O 913; SEROTONIN TRANSPORTER; TROPARIL; TROPOXENE; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; BIOCHEMISTRY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DESIGN; DRUG STRUCTURE; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL;

EID: 10744230248     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.08.055     Document Type: Article

References (49)

1. Arnt J., Christensen A.V., Hyttel J. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. Naunyn- Schmiedeberg's Arch. Pharmacol. 329:1985;101-107.
2. Barker E.L., Moore K.R., Rakhshan F., Blakely R.D. Transmembrane domain I contributes to the permeation pathway for serotonin and ions in the serotonin transporter. J. Neurosci. 19:1999;4705-4717.
3. Bergman J., Madras B.K., Johnson S.E., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates: III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther. 251:1989;150-155.
4. Blough B.E., Abraham P., Mills A.C., Lewin A.H., Boja J.W., Scheffel U., Kuhar M.J., Carroll F.I. 3-Beta-(4-ethyl-3-iodophenyl)nortropane-2 beta-carboxylic acid methyl ester as a high-affinity selective ligand for the serotonin transporter. J. Med. Chem. 40:1997;3861-3864.
5. Burley S.K., Petsko G.A. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science. 229:1985;23-28.
6. Canfield D.R., Spealman R.D., Kaufman M.J., Madras B.K. Autoradiographic localization of cocaine binding sites by [3H]CFT ([3H]WIN 35,428) in the monkey brain. Synapse. 6:1990;189-195.
7. Carroll F.I., Lewin A.H., Boja J.W., Kuhar M.J. Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J. Med. Chem. 35:1992;969-981.
8. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., Niznik H.B., Levey A.I. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15:1995;1714-1723.
9. Daum S.J., Aceto M.D., Clarke R.L. Compounds affecting the central nervous system. 3.3-Phenyltropan-2-ols. J. Med. Chem. 16:1973;667-670.
10. De La Garza R., Meltzer P.C., Madras B.K. Non-amine dopamine transporter probe [(3)H]tropoxene distributes to dopamine-rich regions of monkey brain. Synapse. 34:1999;20-27.
11. Fischman A.J., Bonab A.A., Babich W., Livni E., Alpert N.M., Meltzer P.C., Madras B.K. [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 39:2001;332-342.
12. Freed C., Revay R., Vaughan R.A., Kriek E., Grant S., Uhl G.R., Kuhar M.J. Dopamine transporter immunoreactivity in rat brain. J. Comp. Neurol. 359:1995;340-349.
13. Goulet M., Miller G.M., Bendor J., Liu S., Meltzer P.C., Madras B.K. Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates? Synapse. 42:2001;129-140.
14. Hemby S.E., Co C., Reboussin D., Davies H.M., Dworkin S.I., Smith J.E. Comparison of a novel tropane analog of cocaine, 2 beta-propanoyl-3 beta-(4-tolyl) tropane with cocaine HCl in rats: nucleus accumbens extracellular dopamine concentration and motor activity. J. Pharmacol. Exp. Ther. 273:1995;656-666.
15. Hold K.M., Sirisoma N.S., Ikeda T., Narahashi T., Casida J.E. Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxification. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3826-3831.
16. Hurd Y.L., Kehr J., Ungerstedt U. In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. J. Neurochem. 51:1988;1314-1316.
17. Johanson C.E., Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41:1989;3-52.
18. Kaufman M.J., Spealman R.D., Madras B.K. Distribution of cocaine recognition sites in monkey brain: I. In vitro autoradiography with [3H]CFT. Synapse. 9:1991;177-187.
19. Kitayama S., Shimada S., Xu H., Markham L., Donovan D.M., Uhl G.R. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. U. S. A. 89:1992;7782-7785.
20. Kleven M.S., Anthony E.W., Woolverton W.L. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 254:1990;312-317.
21. Kozikowski A.P., Simoni D., Roberti M., Rondanin R., Wang S., Du P., Johnson K.M. Synthesis of 8-Oxa analogues of norcocaine endowed with interesting cocaine-like activity. Bioorg. Med. Chem. Lett. 9:1999;1831-1836.
22. Lin Z., Wang W., Kopajtic T., Revay R.S., Uhl G.R. Dopamine transporter: transmembrane phenylalanine mutations can selectively influence dopamine uptake and cocaine analog recognition. Mol. Pharmacol. 56:1999;434-447.
23. Madras B.K., Fahey M.A., Bergman J., Canfield D.R., Spealman R.D. Effects of cocaine and related drugs in nonhuman primates: I. [3H]cocaine binding sites in caudate-putamen. J. Pharmacol. Exp. Ther. 251:1989;131-141.
24. Madras B.K., Spealman R.D., Fahey M.A., Neumeyer J.L., Saha J.K., Milius R.A. Cocaine receptors labeled by [3H]2-beta-carbomethoxy-3-beta-(4- fluorophenyl)tropane. Mol. Pharmacol. 36:1989;518-524.
25. Madras B.K., Pristupa Z.B., Niznik H.B., Liang Y., Blundell P., Gonzalez M.D., Meltzer P.C. Nitrogen-based drugs are not essential for blockade of monoamine transporters. Synapse. 24:1996;340-348.
26. Madras B.K., Miller G.M., Meltzer P.C., Brownell A.L., Fischman A.J. Molecular and regional targets of cocaine in primate brain: liberation from prosaic views. Addict. Biol. 5:2000;351-359.
27. Meltzer P.C., Liang A.Y., Brownell A.L., Elmaleh D.R., Madras B.K. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J. Med. Chem. 36:1993;855-862.
28. Meltzer P.C., Liang A.Y., Madras B.K. The discovery of an unusually selective and novel cocaine analog: difluoropine. Synthesis and inhibition of binding at cocaine recognition sites. J. Med. Chem. 37:1994;2001-2010.
29. Meltzer P.C., Liang A.Y., Blundell P., Gonzalez M.D., George C., Madras B.K. 2-Carbomethoxy-3-aryl-8-oxabicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters. J. Med. Chem. 40:1997;2661-2673.
30. Meltzer P.C., Blundell P., Chen Z., Yong Y.F., Madras B.K. Bicyclo[3.2.1]octanes: synthesis and inhibition of binding at the dopamine and serotonin transporters. Bioorg. Med. Chem. Lett. 9:1999;857-862.
31. Meltzer P.C., Blundell P., Huang H., Liu S., Yong F., Madras B.K. 3-Aryl-2-carbomethoxybicyclo[3.2.1]oct-2-enes inhibit WIN 35,428 binding potently and selectively at the dopamine transporter. Bioorg. Med. Chem. 8:2000;581-590.
32. Meltzer P.C., Wang P., Blundell P., Madras B.K. Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate. J. Med. Chem. 46:2003;1538-1545.
33. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 16:1996;436-447.
34. Nirenberg M.J., Chan J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J. Neurosci. 17:1997;4037-4044.
35. Nirenberg M.J., Chan J., Pohorille A., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 17:1997;6899-6907.
36. Reith M.E., Sershen H., Lajtha A. Binding sites for [3H]cocaine in mouse striatum and cerebral cortex have different dissociation kinetics. J. Neurochem. 46:1986;309-312.
37. Reith M.E., Berfield J.L., Wang L.C., Ferrer J.V., Javitch J.A. The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J. Biol. Chem. 276(31):2001;29012-29018.
38. Rice K.C., Wilson R.S. (-)-3-Isothujone, a small nonnitrogenous molecule with antinociceptive activity in mice. J. Med. Chem. 19:1976;1054-1057.
39. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 237:1987;1219-1223.
40. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., Ernsberger P., Rothman R.B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11934-11939.
41. Simoni D., Roberti M., Andrisano V., Manferdini M., Rondanin R., Invidiata F.P. Two-carbon bridge substituted cocaines: enantioselective synthesis, attribution of the absolute configuration and biological activity of novel 6- and 7-methoxylated cocaines. Farmaco. 54:1999;275-287.
42. Smith A.J. The analgesic effects of selective serotonin reuptake inhibitors. J. Psychopharmacol. 12:1998;407-413.
43. Spealman R.D., Madras B.K., Bergman J. Effects of cocaine and related drugs in nonhuman primates: II. Stimulant effects on schedule-controlled behavior. J. Pharmacol. Exp. Ther. 251:1989;142-149.
44. Spealman R.D., Bergman J., Madras B.K., Melia K.F. Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J. Pharmacol. Exp. Ther. 258:1991;945-953.
45. Strader C.D., Dixon R.A. Genetic analysis of the beta-adrenergic receptor. Adv. Exp. Med. Biol. 287:1991;209-220.
46. Strader C.D., Sigal I.S., Candelore M.R., Rands E., Hill W.S., Dixon R.A. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263:1988;10267-10271.
47. Strader C.D., Candelore M.R., Hill W.S., Dixon R.A., Sigal I.S. A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. J. Biol. Chem. 264:1989;16470-16477.
48. Tolliver B.K., Newman A.H., Katz J.L., Ho L.B., Fox L.M., Hsu K. Jr., Berger S.P. Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo. J. Pharmacol. Exp. Ther. 289:1999;110-122.
49. Witkin J.M., Nichols D.E., Terry P., Katz J.L. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J. Pharmacol. Exp. Ther. 257:1991;706-713.